Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia

Journal of Alzheimer's Disease

Volumn 35, Issue 4, 2013, Pages 823-832

  Kryscio, Richard J ^a,b   Abner, Erin L ^a,b   Lin, Yushun ^b,c   Cooper, Gregory E ^a,b,d   Fardo, David W ^b   Jicha, Gregory A ^a,b   Nelson, Peter T ^a,b   Smith, Charles D ^a,b   Van Eldik, Linda J ^a,b   Wan, Lijie ^a,b   Schmitt, Frederick A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Citi Bank   (United States)

^d Baptist Neurology Center   (United States)

Author keywords

Competing events; dementia; mild cognitive impairment; multi state models; risk factors; semi Markov

Indexed keywords

AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMENTIA; ESTROGEN THERAPY; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; UNDERWEIGHT;

EID: 84878850939     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122146     Document Type: Article

References (32)

1. Irie F, Fitzpatrick AL, Lopez OL,Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89-93.
2. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan MN (2003) Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology 22, 13-22.
3. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057-1064.
4. Andersen PK, Geskus RB, de Witte T, Putter H (2012) Competing risks in epidemiology: Possibilities and pitfalls. Int J Epidemiol 41, 861-870.
5. Murphy TE, Han L, Allore HG, Peduzzi PN, Gill TM, Lin H (2011) Treatment of death in the analysis of longitudinal studies of gerontological outcomes. J Gerontol A Biol Sci Med Sci 66, 109-114.
6. Pintile M (2006) Competing Risks, a Practical Perspective, Wiley, Hoboken, N.J.
7. Crowder M (2012) Multivairate survival Analysis and Competing Risks, CRC Press, New York, N.Y.
8. Castelli C, Combescure C, Foucher Y, Daures JP (2007) Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med 26, 5557-5571.
9. Foucher Y, Giral M, Soulillou JP, Daures JP (2007) A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation. Stat Med 26, 5381-5393.
10. Kang M, Lagakos SW (2007) Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics 8, 252-264.
11. Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, Cooper G, Mendiondo M, Danner DD, Van Eldik LJ, Caban-Holt A, Lovell MA,Kryscio RJ (2012) University ofKentucky Sanders-Brown healthy brain aging volunteers: Donor characteristics, procedures and neuropathology. Curr Alzheimer Res 9, 724-733.
12. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR (2006) Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 66, 828-832.
13. Jicha GA, Abner E, Schmitt FA, Cooper GE, Stiles N, Hamon R, Carr S, Smith CD, Markesbery WR(2008) Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord 26, 187-192.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
15. Foucher Y, Giral M, Soulillou JP, Daures JP (2010) A flexible semi-Markov model for interval-censored data and goodnessof-fit testing. Stat Methods Med Res 19, 127-145.
16. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
17. Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harbor Perspect Med 2, a006239.
18. Beach TG, Monsell SE, Phillips LE, KukullW(2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.
19. Purnell C, Gao S, Callahan CM, Hendrie HC (2009) Cardiovascular risk factors and incident Alzheimer disease: A systematic review of the literature. Alzheimer Dis Assoc Disord 23, 1-10.
20. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women:Women's Health Initiative Memory Study. JAMA 291, 2947-2958.
21. Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA,Kuller LH, Margolis KL, Mysiw WJ, Maldjian JA, Melhem ER, Resnick SM(2009) Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci 64, 1243-1250.
22. Shao H, Breitner JCS, Whitmer RA, Wang J, Hayden K, Wengreen H, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP, For the Cache County, Invesitgators (2012) Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study. Neurology 79, 1846-1852.
23. Luchsinger J, Reitz C, Patel B, Tang M, Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Archi Neurol 64, 570-575.
24. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, Keller JN, Jicha GA, Davis D, Wang-Xia W, Hartman A, Katz DG, Markesbery WR (2009) Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792, 454-469.
25. Williams JW, Plassman BL, Burke J, Benjamin S (2010) Preventing Alzheimer's disease and cognitive decline. Evid Rep Technol Assess (Full Rep) 1-727.
26. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
27. Nelson P, Head E, Schmitt F, Davis P, Neltner J, Jicha G, Abner E, Smith C, Van Eldik L, Kryscio R, Scheff S (2011) Alzheimer's disease is not "brain aging": Neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121, 571-587.
28. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOEgene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
29. Singh-Manoux A, Czernichow S, Elbaz A, Dugravot A, Sabia S, Hagger-Johnson G, Kaffashian S, Zins M, Brunner EJ, Nabi H, Kivimaki M (2012) Obesity phenotypes in midlife and cognition in early old age: The Whitehall II cohort study. Neurology 79, 755-762.
30. Yu L, Tyas SL, Snowdon DA, Kryscio RJ (2009) Effects of ignoring baseline on modeling transitions from intact cognition to dementia. Comput Stat Data Anal 53, 3334-3343.
31. Abner EL, Kryscio RJ, Cooper GE, Fardo DW, Jicha GA, Mendiondo MS, Nelson PT, Smith CD, Van Eldik LJ, Wan L, Schmitt FA (2012) Mild cognitive impairment: Statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis 2012, 291920.
32. Yu L, Griffith WS, Tyas SL, Snowdon DA, Kryscio RJ (2010) A nonstationary Markov transition model for computing the relative risk of dementia before death. Stat Med 29, 639-648.